Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2 Expressing Advanced Malignant Solid Tumors
NCT06293898Phase 1Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BL-M07D1 in solid tumor, endometrial cancer (EC), Cervical Cancer (CC) and 8 more (3 arms), sponsored by SystImmune Inc. Primary endpoints: Summary of safety at 24 months and Maximum Tolerated Dose or Maximum Administered Dose at 21 days. Started Feb 2024; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
solid tumorendometrial cancer (EC)Cervical Cancer (CC)ovarian cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06293898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293898.